摘要
Abstract
OBJECTIVE:To evaluate the short-term efficacy and safety of nucleoside antiviral therapy for hepatitis B virus-associated cirrhosis.METHODS: 50 patients with liver cirrhosis treated in hospital from January 2009 to January 2011 were assigned to receive routine therapy ( control group); another 100 patients with hepatitis B virus-associated cirrhosis ( observation group) treated in our hospital from January 2011 to January 2013 were assigned to receive lamivudine ( subgroup A) , adefovir ( subgroup B) or entecavir ( subgroup C) .Four groups were observed and compared before and after treatment with regard to liver function [ alanine aminotransferase ( ALT ) , aspartate aminotransferase (AST), total bilirubin (TBIL), albumin (ALB)], prothrombin time activity (PTA), liver fibrosis [hyaluronic acid (HA), laminin (LN), Ⅲ procollagen (PC-Ⅲ), Ⅳ collagen (Ⅳ-C)], HBV-DNA negative rate and HBeAg seroconversion rate.RESULTS: After treatment, the liver function and liver fibrosis in all of the four groups improved significantly, much as in three subgroups ( group A, B and C ) , showing statistically significant differences between the observation group ( three subgroups ) and the control group ( P<0.05 ) , yet the differences among the three subgroups were not statistically significant ( P >0.05 ); HBV-DNA negative rate and HBeAg seroconversion rates in three subgroups were significantly higher than in the control group after treatment and the differences were statistically significant ( P<0.05 ) , yet the differences were not statistically significant among three subgroups ( P>0.05 ) .The cost-effectiveness analysis on the three subgroups showed that subgroup C took the lead in C/E value ( 2538.0 ) , showing statistically significant differences as compared with the other two subgroups ( P <0.05 ) .The three subgroups in the observation group presented with only mild adverse drug reactions such as myalgia and mild fatigue.CONCLUSION:Nucleoside antiviral therapy is safe and effective for patients with hepatitis B virus-associated cirrhosis in that which can effectively improve patients'liver function and prevent liver fibrosis; entecavir can be used as the preferred choice economically, and which is worthy of popularization in clinical application.关键词
核苷类抗病毒药物/乙肝肝硬化/近期疗效/安全性Key words
Nucleoside antiviral therapy/Hepatitis B virus-associated cirrhosis/Short-term efficacy/Safety分类
医药卫生
